To inspire and empower millions of people living with Parkinson’s around the world, Bial launches a touching campaign for the World Parkinson’s Day showing that it is possible to live a normal life, and successfully perform everyday tasks
Imagine being unable to control your own body. In your mind, everything is exactly like it was; but your brain seems to have forgotten how to tell your body to do everyday tasks like tying up shoes or using a toothbrush.
This is how it feels to live with Parkinson’s. A real challenge for the 10 million people diagnosed with Parkinson’s around the world. Parkinson’s is a progressive neurodegenerative disease – an illness that affects nerve cells in the brain. For those who live with these symptoms and for their families, Parkinson’s means much more than just physical symptoms: it also means a loss of their independence.
In order to raise awareness and help people keep their self-esteem, people with Parkinson’s were invited to star in a video that shows them at their best by focusing on what they can do instead of what they cannot do. Buttoning up shirts, putting on make-up, tying up shoes or even dancing and playing musical instruments. Simple, everyday tasks alongside a cheerful, feel-good tune developed specially for the campaign.
António Portela, CEO of Bial, explains the positive tone of the campaign: “Parkinson’s can really change people’s lives, but it’s very important that they do not lose their self-esteem. That is why we wanted to counter the negative portraits of people with Parkinson’s and show everyone what they really can do. Hopefully, we can inspire and empower the millions of people living with Parkinson’s to never give up on their dignity. Bial’s aim is to help the lives of people with Parkinson’s even if it’s to help with one small thing at a time.”
The campaign launches worldwide today – on World Parkinson’s Day – and is featured on Bial’s website, across Bial’s social media and on the European Parkinson’s Disease Association’s social media channels too.
Watch the video ‘Me at my best’ below
This article is sponsored by Bial. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Founded in 1924, Bial’s mission is to discover, develop and provide therapeutic solutions within the area of health. In recent decades, Bial has strategically focused on quality, innovation and internationalisation. Bial has channelled more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system.
In 2016 Bial launched Opicapone for Parkinson’s disease. Already available in Germany and in the United Kingdom, it will be introduced in the remaining European countries throughout 2017.
Currently representing around two thirds of its turnover, Bial will continue to strengthen its international presence based in its own innovative medicines, particularly in the most important European pharmaceutical markets, Spain, Germany, United Kingdom and Italy, where the company is already present with its own affiliates. For more information about Bial, please visit www.bial.com.
Doctors thought I had Parkinson’s for nearly a decade – they were wrong
What's it like to think you had Parkinson's for nearly a decade?
3 days ago
Smartphone test predicts development of Parkinson’s symptoms, study says
Researchers have created a smartphone test that may be able to predict the development of Parkinson’s symptoms. The study – carried out by researchers from the University of Oxford and funded by the Monument Trust Discovery Award from charity Parkinson’s UK – used the test to assess voice, balance, walking and reaction time in people living with Parkinson’s. The results indicated that the test may be able to predict development of Parkinson’s symptoms up to 18 months before they occur. Researchers hope this will allow healthcare professionals to tailor a more personalised approach to the treatment of Parkinson’s. Christine Lo, clinical research fellow at the University of Oxford’s Oxford Parkinson’s Disease Centre, said: “The main driver for this study was to improve clinical care by finding better ways of predicting how Parkinson’s is likely to progress over time on an individual basis, as its course can vary greatly from person to…
The European Parkinson’s Disease Association (EPDA) is inviting carers from within the Parkinson’s community to take part in a survey aiming to shine a light on the physical, financial and emotional difficulties they face. The research – supported by French healthcare devices company Air Liquide – will be used to inform future campaigns and create valuable tools to help carers and the wider Parkinson’s community. Russell Patten, the secretary general of the EPDA, said: “Carers are such an important part of the Parkinson’s community – they provide the firm foundations that support their loved ones who are physically living with the condition. “However, carers’ needs and quality of life are sadly, all too often, overlooked; this can lead to devastating and lasting effects on the individual and the wider society.” The survey is open until 6 September 2019, and is available in English, French, German Italian, Danish, Dutch, Portuguese, Slovenian…
Scottish university reveals multimillion-pound Parkinson’s research partnership
The University of Dundee, UK, has announced a collaboration with South Korean pharmaceutical company Bukwang to develop a new treatment for Parkinson’s. Collaborating with researchers at the University of Oxford, UK, the university’s drug discovery unit (DDU) has found molecules that may reduce levels of a protein closely connected to the development of the condition. The new partnership will build on this existing relationship between the universities – and facilitate a further three-year Parkinson’s research programme which will move the molecules towards clinical development. Professor Paul Wyatt, head of the DDU, said: “Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together. “This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug-discovery capabilities, allowing us to move one stage further towards a treatment.”